News Search Results
Oct 29, 2025, 14:58 ET Sepsis Diagnostics Market to Reach USD 1,790.9 million by 2032, Growing At An 7.85% CAGR - Credence Research
highly competitive and innovative field, populated by a mix of large, diversified in-vitro diagnostics (IVD) corporations and smaller, specialized biotechnology firms. Industry giants such as bioMérieux SA, Becton, Dickinson and Company (BD), Abbott Laboratories, Danaher Corporation (through its subsidiaries
More news about: Credence Research Inc.
Oct 29, 2025, 14:40 ET Profiling Biology at Scale with DRUG-seq: From Mechanisms to Safety, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 29, 2025, 14:30 ET Accelerating Radiopharmaceutical Therapy with Translational Tools, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 29, 2025, 14:30 ET Boost Participant Recruitment with Precision Feasibility and RWD, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 29, 2025, 14:22 ET Digital Pathology Market Size to Surpass USD 6.55 Billion by 2035, Rising at a CAGR of 17.15% | Report by Vantage Market Research
imaging resolution and workflow efficiency. Forge Strategic Alliances Across the Diagnostic Value Chain – Partner with biotechnology companies, hospitals, and AI developers to validate digital workflows, integrate automated systems, and accelerate adoption in high-growth healthcare
More news about: Vantage Market Research
Oct 29, 2025, 12:05 ET Valthos Raises $30M from OpenAI, Lux Capital, Founders Fund to Build Next-Generation Biodefense
Kathleen McMahon, former head of Palantir's Life Sciences division, Valthos brings together a team spanning software engineering, ML development, and biotechnology. The founding team consists of engineers from Palantir and DeepMind, and computational biologists from Stanford's Arc Institute and MIT's Broad
More news about: Valthos Inc
Oct 29, 2025, 10:30 ET Iris Ventures Makes Multimillion-Dollar Investment in Goddess Maintenance Co., Pioneering a New Era of "Bioprotection" in Hair Care
breakthrough hair care brands Olaplex and K18, joined forces with sisters Vesler and Mason to create a next-generation professional system grounded in biotechnology. At the heart of the brand is the Goddess Molecule, developed in partnership with biomaterials innovation leader, Bolt. Inspired
More news about: Goddess Maintenance Co.
Oct 29, 2025, 10:30 ET Lilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United States
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Oct 29, 2025, 09:00 ET FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria
About BioMarin BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based
More news about: BioMarin Pharmaceutical Inc.
Oct 29, 2025, 08:39 ET CounterX Therapeutics Announces Publication Demonstrating CTRX-101, an Anti-Fentanyl Monoclonal Antibody Therapy, Reverses Fentanyl-Induced Overdose in Preclinical Model
SEATTLE, Oct. 29, 2025 /PRNewswire/ -- CounterX Therapeutics, Inc., a biotechnology company focused on developing novel antibody therapeutics and vaccines to address opioid overdose and dependence, today announced the publication
More news about: CounterX Therapeutics
Oct 29, 2025, 08:34 ET GeneVentiv Therapeutics Announces Positive FDA INTERACT Feedback Supporting Advancement of GENV-HEM Gene Therapy for Hemophilia A with or without Inhibitors
RALEIGH, N.C., Oct. 29, 2025 /PRNewswire/ -- GeneVentiv Therapeutics, Inc., a privately held biotechnology company developing one-time gene therapies for rare and inherited diseases, today announced that it held a successful INTERACT meeting with the
More news about: GeneVentiv Therapeutics
Oct 29, 2025, 08:33 ET GlycoNex Announces Last Patient Dosed in Phase 3 Trial of SPD8, a Denosumab Biosimilar for Osteoporosis
commercialization collaborations. About GlycoNex Inc. GlycoNex Inc. is a clinical-stage biotechnology company focused on the development of glycan-directed cancer immunotherapies that effectively inhibit tumor growth while minimizing side effects.
More news about: GlycoNex, Inc.
Oct 29, 2025, 08:30 ET Miami Biotech Collective Introduces Board of Advisors and Women's Leadership Council to Shape South Florida's Biotech Future
companies, careers, and innovation thrive. Together, alongside local and statewide partners, we are positioning South Florida as a leading hub for biotechnology. Learn more at
More news about: Miami Biotech Collective
Oct 29, 2025, 08:05 ET Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update
About Rigel Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders
More news about: Rigel Pharmaceuticals, Inc.
Oct 29, 2025, 08:00 ET Numerion Labs Publishes Breakthrough AI Research on Ultra-Fast Screening of Hyper-Scalable Virtual Libraries with NVIDIA
targets, including kinases, GPCRs, proteases and nuclear receptors. These advances have the potential to fundamentally reshape how pharmaceutical and biotechnology companies approach hit discovery by enabling comprehensive, real-time exploration of chemical space. This, in turn, can accelerate progression to
More news about: Numerion Labs
Oct 29, 2025, 07:05 ET REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights
advised to join 15 minutes prior to the start time. ABOUT REGENXBIO Inc. REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Oct 29, 2025, 07:00 ET Inari Appoints Lisa Nunez Safarian Chief Executive Officer
Sana Biotechnology,
More news about: Flagship Pioneering
Oct 29, 2025, 07:00 ET LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Oct 29, 2025, 06:30 ET Immunic to Participate in Industry and Investor Conferences in November
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today
More news about: Immunic, Inc.
Oct 29, 2025, 05:01 ET IASO Bio Partners with Korea's GC Cell to Bring CAR-T Therapy to Korea
About IASO Biotechnology IASO Biotechnology is a China-based biopharmaceutical company dedicated to the discovery, development, production and commercialization
More news about: IASO Bio
Oct 29, 2025, 02:59 ET MGI Tech Announces Exclusive Licensing Agreement with Swiss Rockets AG to Globalize Proprietary CoolMPS™ Sequencing Technology
focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and a full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare, and various
More news about: MGI TECH
Oct 29, 2025, 02:03 ET Insilico Showcases Advanced Generative Biologics Engine in Breakthrough 72-Hour Peptide Design Targeting GLP1R for Cardiometabolic Disease
critical health challenges. In alignment with this year's theme of "Diabetes and Well-being," Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), is harnessing its proprietary AI engine
More news about: Insilico Medicine
Oct 28, 2025, 22:31 ET "Korea Night" to Bring Global Bio Leaders Together at BIO Europe 2025
opening day of BIO Europe 2025—the largest biotechnology partnering conference in Europe—welcoming participants from across Europe and around the world. Since its launch in 1995, BIO Europe has become one of the world's leading biotechnology partnering events, alongside BIO USA. This
More news about: Korea Night
Oct 28, 2025, 19:00 ET Pinetree Therapeutics Raises $47 Million in Oversubscribed Series B to Advance Next-Generation Protein Degraders in Oncology
CAMBRIDGE, Mass., Oct. 28, 2025 /PRNewswire/ -- Pinetree Therapeutics, a preclinical-stage biotechnology company pioneering targeted protein degraders for drug-resistant cancers, announced the successful closing of an oversubscribed $47 million Series
More news about: PineTree Therapeutics
Oct 28, 2025, 18:00 ET Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets
About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics